Ken Griffin Editas Medicine, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 45,200 shares of EDIT stock, worth $210,632. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,200
Previous 159,800
71.71%
Holding current value
$210,632
Previous $1.62 Million
79.3%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding EDIT
# of Institutions
243Shares Held
69.3MCall Options Held
564KPut Options Held
428K-
State Street Corp Boston, MA8.76MShares$40.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.56MShares$39.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.83MShares$36.5 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.53MShares$25.8 Million1.35% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.61MShares$12.2 Million0.01% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $320M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...